Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Campagnaro E, Castillo JJ, Costello C, D’Angelo C, Devarakonda S, et al. Systemic light chain Amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(1):67–81.
Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022;17(1):278.
Hou HA, Tang CH, Goh CH, Shen SP, Huang KC, Qiu H, Siggins S, Rothwell LA, Liu Y. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan. Sci Rep. 2022;12(1):15736.
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–32.
Suzuki K, Wechalekar AD, Kim K, Shimazaki C, Kim JS, Ikezoe T, Min CK, Zhou F, Cai Z, Chen X, et al. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. Ann Hematol. 2023;102(4):863–76.
Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere. 2020;4(4):e454.
Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2015;13(11):1195–211.
Shen K, Tian Z, Gao Y, Wang Y, Huo L, Li J, Zhang Y, Zhang S. Chinese consensus on the diagnosis and treatment of Immunoglobulin light-chain cardiac amyloidosis. Chin Med J (Engl). 2024;137(2):127–9.
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.
Fotiou D, Theodorakakou F, Kastritis E. Biomarkers in AL amyloidosis. Int J Mol Sci 2021, 22(20).
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–328.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, et al. New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, Galderisi M, Marwick T, Nagueh SF, Sengupta PP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese society of echocardiography. J Am Soc Echocardiogr. 2011;24(3):277–313.
van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, Reitsma JB. Sample size for binary logistic prediction models: beyond events per variable criteria. Stat Methods Med Res. 2019;28(8):2455–74.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, et al. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2021;28(1):3–11.
Charliński G, Steinhardt M, Rasche L, Gonzalez-Calle V, Peña C, Parmar H, Wiśniewska-Piąty K, Dávila Valls J, Olszewska-Szopa M, Usnarska-Zubkiewicz L, et al. Outcomes of modified Mayo stage IIIa and IIIb cardiac light-chain amyloidosis: real-world experience in clinical characteristics and treatment—67 patients multicenter analysis. Cancers (Basel). 2024;16(8).
Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: A review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–41.
Lei C, Zhu X, Hsi DH, Wang J, Zuo L, Ta S, Yang Q, Xu L, Zhao X, Wang Y, et al. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021;21(1):43.
雷常慧. 朱晓丽, 刘丽文, 左蕾, 杨帆, 王妍, 马志玲 超声心动图结合血清学指标在高危原发性轻链型心肌淀粉样变中的预后价值. Chin J Ultrasound Med. 2019;35(11).
Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, Chen CL, Yu AF, Steingart RM, Liu JE. Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis. JACC CardioOncol. 2020;2(2):223–31.
Li X, Liu X, Feng X, Guo T, Liu G, Wu D, Lin X, Fang L, Chen W. Prognostic value of echocardiographic cardiac chamber longitudinal strains in advanced light chain cardiac amyloidosis. Hellenic J Cardiol. 2024 Dec 15:S1109-9666(24)00267-7.
Wan K, Lin J, Guo X, Song R, Wang J, Xu Y, Li W, Cheng W, Sun J, Zhang Q, et al. Prognostic value of right ventricular dysfunction in patients with AL amyloidosis: comparison of different techniques by cardiac magnetic resonance. J Magn Reson Imaging. 2020;52(5):1441–8.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008;83(3):297–303.
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12–18.
Ramachandran R, Grantham T, Isaac-Coss G, Etienne D, Reddy M. Gastroduodenal involvement in AL amyloidosis: case report and literature review. J Investig Med High Impact Case Rep. 2024;12:23247096241237759.
Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med. 2001;111(7):535–40.
中国系统性轻链型淀粉样变性协作组, 国家肾脏疾病临床医学研究中心, 国家血液系统疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南(2021年修订). 中华医学杂志. 2021;101(22):1646–56.
中国系统性淀粉样变性协作组, 国家肾脏疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南. 中华医学杂志. 2016;96(44):3540–8.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.
Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215–23.